DCF Help. Biotech case study

Valuation Case Study

For this case study, we would like you to calculate the suggested ownership of “Investor B” in a biotech startup “Company A” following a $10m investment in 2017.

Please use the following assumptions:
• Product Target Profile:
Company A is developing a drug for osteoarthritis, a common orthopedic indication
• Timing of Clinical Development:
The company was founded in 2012, when it filed its patent on the drug, just passed pre-clinical studies in animals and is now about to start its Phase I clinical studies. There will be 3 clinical study phases before approval. Expectation is to get market approval in 8 years, i.e. on 01-Jan-2025
• Financials:
Expected costs for the next 8 years (to get to market) are $40m. Expected peak sales in 10 years from, i.e. in FY2027 are $200m. Expected EBITDA in in FY2027 is $100m . Once the drug is on the market, please just make your own rough assumptions for COGS and SG&A (without any greater detail)
• Investment
Investor A already invested $50m in 2012, thereof $30m as equity (common stock) and $20m as debt (assuming no interest to be paid). Cash at the company before Investor B’s investment is $15m. Investor B is now investing $10m.

For Investor B investing $10m now as equity (common stock), what is the ownership in Company A you believe he should receive?

Assumptions:
Please just make rough assumptions for all other variables you believe you need (e.g. COGS, etc.).

 

Ab ducimus qui repellat consequuntur. Expedita aut ut fugit voluptatum assumenda esse est. Quia ut qui incidunt dolores delectus et itaque. Quidem id necessitatibus vel eaque similique quos. Corporis ad minus iste. Neque quo impedit incidunt.

Neque eos et incidunt aut et eligendi rem. Vero et voluptatem optio qui officia qui. Incidunt et perferendis nemo sapiente dolorem. Deleniti id explicabo aut recusandae rerum ut veniam aut.

Est qui temporibus ad harum aperiam. Quam magni ipsam ratione accusamus quis animi sit sunt.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Secyh62's picture
Secyh62
99.0
4
Betsy Massar's picture
Betsy Massar
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
kanon's picture
kanon
98.9
9
Linda Abraham's picture
Linda Abraham
98.8
10
DrApeman's picture
DrApeman
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”